PR Newswire报道,Pomerantz LLP宣布已对ARS Pharmaceuticals, Inc.("ARS"或"公司")(NASDAQ: SPRY)提起集体诉讼。受损失的投资者被建议联系Danielle Peyton,邮箱为newactionpomlaw.com或拨打646-581-9980。
PR Newswire报道,Pomerantz LLP宣布已对ARS Pharmaceuticals, Inc.("ARS"或"公司")(NASDAQ: SPRY)提起集体诉讼。受损失的投资者被建议联系Danielle Peyton,邮箱为newactionpomlaw.com或拨打646-581-9980。